ASC
VRTX icon

Atalanta Sosnoff Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Atalanta Sosnoff Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-773
Closed -$350K – 117
2025
Q4 		$350K Buy
773
+2
+0.3% +$862 0.01% 87
2025
Q3 		$302K Sell
771
-30,985
-98% -$12.9M 0.01% 92
2025
Q2 		$14.1M Sell
31,756
-11,939
-27% -$5.5M 0.29% 48
2025
Q1 		$21.2M Sell
43,695
-1,507
-3% -$702K 0.51% 48
2024
Q4 		$18.2M Sell
45,202
-74,236
-62% -$34.4M 0.4% 48
2024
Q3 		$55.5M Sell
119,438
-41,817
-26% -$20.1M 1.19% 29
2024
Q2 		$75.6M Sell
161,255
-6,800
-4% -$2.95M 1.7% 15
2024
Q1 		$70.2M Sell
168,055
-7,606
-4% -$3.22M 1.62% 19
2023
Q4 		$71.5M Buy
175,661
+54,043
+44% +$20M 1.84% 16
2023
Q3 		$42.3M Sell
121,618
-2,757
-2% -$964K 1.25% 29
2023
Q2 		$43.8M Buy
124,375
+3,242
+3% +$1.09M 1.19% 29
2023
Q1 		$38.2M Buy
121,133
+8,899
+8% +$2.67M 1.11% 37
2022
Q4 		$32.4M Sell
112,234
-11,420
-9% -$3.48M 1% 42
2022
Q3 		$35.8M Buy
+123,654
New +$35.6M 1.13% 33
2020
Q2 		– Sell
-71,310
Closed -$17M – 112
2020
Q1 		$17M Sell
71,310
-1,535
-2% -$352K 0.6% 54
2019
Q4 		$15.9M Sell
72,845
-137,136
-65% -$27.8M 0.47% 56
2019
Q3 		$35.6M Sell
209,981
-6,134
-3% -$1.09M 1.15% 36
2019
Q2 		$39.6M Sell
216,115
-7,019
-3% -$1.23M 1.25% 34
2019
Q1 		$41M Sell
223,134
-82,338
-27% -$15.2M 1.28% 37
2018
Q4 		$50.6M Sell
305,472
-1,351
-0.4% -$234K 1.84% 21
2018
Q3 		$59.1M Sell
306,823
-527
-0.2% -$93.8K 1.77% 21
2018
Q2 		$52.2M Sell
307,350
-257,433
-46% -$39.9M 1.72% 24
2018
Q1 		$92M Buy
564,783
+93,641
+20% +$15.3M 3.07% 8
2017
Q4 		$70.6M Buy
471,142
+81,541
+21% +$12.1M 2.29% 16
2017
Q3 		$59.2M Buy
389,601
+101,517
+35% +$15.3M 2.05% 19
2017
Q2 		$37.1M Buy
+288,084
New +$34.7M 1.31% 31

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Atalanta Sosnoff Capital's VRTX Position: Q1 2026 in Review

Atalanta Sosnoff Capital sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 773 shares — an estimated $350K sold.

Atalanta Sosnoff Capital first reported a position in VRTX in Q2 2017 and held it in 26 quarters. The position peaked at $92M in Q1 2018. 1,695 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Atalanta Sosnoff Capital reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Atalanta Sosnoff Capital sold 773 Vertex Pharmaceuticals shares in Q1 2026, an estimated $350K.
  • Atalanta Sosnoff Capital first reported a position in Vertex Pharmaceuticals in Q2 2017 and held it in 26 quarters.
  • Atalanta Sosnoff Capital's Vertex Pharmaceuticals position peaked at $92M in Q1 2018.
  • 1,695 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Atalanta Sosnoff Capital's 13F filing for Q1 2026, filed 15 May 2026.